We are aiming to innovate PET diagnostic imaging by transforming blood flow quantification.
MedTrace Pharma A/S was founded with the belief that we can improve diagnostic accuracy in PET perfusion examinations to the benefit of patients globally. It is our ambition to make 15O-water PET clinically available for all cardiac patients and to help usher in a new era in diagnostic medicine.
MedTrace is currently preparing for a confirmatory multi-center pivotal Phase III trial in cardiology evaluating 15O-water PET versus invasive coronary angiography and current best practice SPECT imaging. The trial will be conducted under an IND with FDA supervision and includes patients from EU, North America and Japan.
Safety is paramount in healthcare. MedTrace believes that 15O-water PET will be proven as a safe alternative to other imaging techniques, and that the low radiation burden of 15O-water will be beneficial to the common health of the population.
With an aging population, healthcare efficiency is more important than ever. By shortening the overall procedure time for patients and staff as well as raising the accuracy, MedTrace intends to raise healthcare efficiency.
The MedTrace Team
Meet our team and learn about our backgrounds.
Read about our partners, investors and grants we have received.
”The availability of a reliable approved system for bed-side production of 15O-water could change 15O-water PET from an exotic research tool to a clinical workhorse”
Martin Stenfeldt, CEO, MedTrace Pharma